AQW-051

N/A

Report date: 2025/10/29 20:02:15
NME

Base Information

Drug NameAQW-051
Drug Alias NameAQW-051VQW-765
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuronal acetylcholine receptor protein alpha-7 subunit agonists
TargetsNeuronal acetylcholine receptor protein alpha-7 subunit
Therapy Area/IndicationsSchizophreniaCognitive DysfunctionPerformance Anxiety +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSouth Africa +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesVanda Pharmaceuticals Inc
Inactive CompaniesNovartis Pharma Ag
Active IndicationsPerformance AnxietyAnxiety
Inactive IndicationsSchizophreniaCognitive DysfunctionDyskinesias +[4] 

Other Information

ATC CodeN/A
Related LinksN/A